This article first appeared on GuruFocus .
-
Revenue Growth:Q3 was the strongest revenue quarter of 2025, with a 50% increase over Q2.
-
Lead Generation:Year-to-date lead generation up 22% compared to last year.
-
International Revenue Contribution:Revenue from academia outside the US increased to 20% year-to-date, up from 5% earlier this year.
-
OEM Revenue:Revenue from existing OEM collaborations approaching six figures year-to-date.
-
Customer Base:More than 400 customers, with over half of year-to-date sales from existing customers expanding their systems.
-
Product Launch:First batch of 500 dissolved oxygen nanoparticle units sold out.
Release Date: November 20, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Scientific Industries Inc ( SCND ) successfully divested its legacy Genie products division, marking a significant strategic shift.
-
The company introduced a new AI-driven feature to its VIVID Workstation, enhancing regulatory compliance and cost savings for customers.
-
The DOTS platform is gaining strategic interest from biomanufacturing organizations, highlighting its potential in AI and advanced analytics.
-
Q3 2025 was the strongest revenue quarter of the year, with a 50% increase over Q2, indicating improving sales performance.
-
The company is seeing increased OEM collaborations and interest in integrating DOTS into next-generation systems, suggesting future growth opportunities.
Negative Points
-
The bioprocessing segment continues to face a challenging market environment with tight budgets and high competition for funding.
-
New technologies face higher adoption hurdles due to risk-averse customers and the need for mature, robust products.
-
The market environment remains selective and cost-cautious, impacting capital spending decisions.
-
Q3 reflected typical industry seasonality, leading to a softer top of the funnel compared to the first half of the year.
-
Despite improvements, the overall market is normalizing only gradually, indicating ongoing external challenges.
Q & A Highlights
Q: Can you provide an update on the transition following the divestiture of the Genie products division? A: Helena Santos, CEO, explained that the company is assisting the buyer with the transition of production, engineering, customers, and suppliers. The process is expected to be completed in the next three to six months, with the final installment of the sale price secured during this period.
Q: What are the recent developments in the Benchtop Lab Equipment Operations? A: Helena Santos, CEO, highlighted the introduction of a new AI-driven feature to the VIVID Workstation, which offers customers actionable insights, strengthens regulatory compliance, and delivers cost savings. This is part of their strategy to position VIVID as the premier pill counting solution in the market.
Q: How is the bioprocessing segment performing, and what are the future expectations? A: Daniel Donadille, CEO of Bioprocessing Operations, noted that the market remains challenging with tight budgets and high competition for funding. However, there is growing strategic interest in their platform, particularly in AI and advanced analytics. The focus is on completing the DOTS platform and ensuring products meet high customer validation standards before scaling.
Q: Can you elaborate on the progress of the DOTS platform? A: Daniel Donadille, CEO of Bioprocessing Operations, reported solid progress in R&D, including algorithmic upgrades for the BioR 2 biomass sensor and production optimization of DO nanoparticles. The platform is expanding into new markets, and customer feedback has been positive, indicating a strong product-market fit.
Q: What are the commercial highlights for the third quarter? A: Daniel Donadille, CEO of Bioprocessing Operations, mentioned that Q3 was the strongest revenue quarter of 2025, with a 50% increase over Q2. There is a slight rebound in academia outside the US, and the launch of dissolved oxygen nanoparticles has expanded their market. OEM channels are gaining traction, and there is rising interest from companies exploring data-driven bioprocessing.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
